Curative Biotechnology Past Earnings Performance
Past criteria checks 0/6
Curative Biotechnology's earnings have been declining at an average annual rate of -14.1%, while the Biotechs industry saw earnings growing at 19.7% annually.
Key information
-14.1%
Earnings growth rate
-7.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Curative Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -6 | 2 | 0 |
| 31 Dec 22 | 0 | -5 | 2 | 2 |
| 30 Sep 22 | 0 | -6 | 2 | 2 |
| 30 Jun 22 | 0 | -6 | 2 | 2 |
| 31 Mar 22 | 0 | -19 | 4 | 1 |
| 31 Dec 21 | 0 | -19 | 4 | 1 |
| 30 Sep 21 | 0 | -22 | 8 | 0 |
| 31 Mar 21 | 0 | -17 | 5 | 0 |
| 31 Dec 20 | 0 | -5 | 5 | 0 |
| 31 Mar 20 | 0 | 1 | 0 | 0 |
| 31 Dec 19 | 0 | 0 | 0 | 0 |
| 31 Dec 14 | 0 | 0 | 0 | 0 |
| 31 Mar 14 | 0 | 0 | 0 | 0 |
| 31 Dec 13 | 0 | 0 | 0 | 0 |
| 30 Sep 13 | 0 | 0 | 0 | 0 |
Quality Earnings: CUBT is currently unprofitable.
Growing Profit Margin: CUBT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CUBT is unprofitable, and losses have increased over the past 5 years at a rate of 14.1% per year.
Accelerating Growth: Unable to compare CUBT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CUBT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: CUBT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.